Towards a malaria vaccine: riding the rollercoaster between unrealistic optimism and lethal pessimism.
Activity in many laboratories over the past decade has resulted in many vaccine candidates nearing clinical trials. These include several antigens from the sporozoite stage; merozoite surface antigens MSA1 and MSA2, RESA, the rhoptry proteins RAP-1 and RAP-2 from the asexual blood stage; the pfs25, pfg45 and pfg230 from the ookinete and gamete stages. This progress in the identification of potential vaccine candidates now highlights a series of scientific, developmental, economic and operational problems the solutions to which will be as critical to the development of a vaccine as the cloning and expression of parasite genes.
Saul
A
A
Tropical Health Program, Queensland Institute of Medical Research, Brisbane, Australia.
D000818:Animals; D006801:Humans; D008288:Malaria / Q000276:immunology / Q000517:prevention & control*; D010961:Plasmodium / Q000187:drug effects / Q000276:immunology*; D016052:Protozoan Vaccines / Q000276:immunology / Q000494:pharmacology
D016052:Protozoan Vaccines